We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Unknown Manufacturer
CTX130 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD70 antigen.
